Laser microdissection and two-dimensional difference gel electrophoresis with alkaline isoelectric point immobiline gel reveals proteomic intra-tumor heterogeneity in colorectal cancer  by Yonemori, Hirotaka et al.
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To approach heterogeneity of tumor tissues, we examined proteomes of normal and tumor
tissues  from colorectal cancer patients by laser microdissection and 2D-DIGE with saturation
dye  and alkaline range IPG gel. By distinguishing the tumor cells based on tissue localiza-
tion,  we found that a range of protein spots showed different intensity between normal
and  diseased tissues. Subsequent mass spectrometric protein identiﬁcation identiﬁed the
proteins for protein spots. We  found that the protein spots from identical proteins showed
the  different tissue localization in colorectal cancer. These results highlight the potential
utilities  of laser microdissection, 2D-DIGE, and immobilized pH gradient gel with alkalinentra-tumor heterogeneity
aser  microdissection
wo-dimensional difference gel
lectrophoresis
lkaline pI range IPG gel
range.
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akes  it one of the most common types of cancer world-
ide  [1]. Intensive treatments have been developed to improve
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lar  targeting drugs, such as those against epidermal growth
factor  receptor [3,4] and the vascular endothelial growth fac-ail.com (T. Kondo).
tor  protein [5], have shown clinical beneﬁts. In addition,
the  introduction of new cytotoxic agents such as oxaliplatin
and  irinotecan has contributed to the prolonged survival
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Table 1 – Summary of the clinical and pathological data
of the 19 colorectal cancer patients.
All cases (n = 19)
Age
Median (range) 66 (44–76)
Sex
Male 15
Female 4
Location
Colon 12
Rectum 7
Histological grading
Well differentiated 10
Moderately differentiated 8
Poorly differentiated 1
Depth of invasiona
T1 1
T2 2
T3 16
Stageb
I 1
II 4
III 13
IV 1
a T1: tumor invades submucosa; T2: tumor invades muscularis; T3:
tumor invades through the muscularis propria into the subserosa,18  e u  p a o p e n p r o t e 
of patients with metastatic CRC [6,7]. Unfortunately, the
responses to these treatments are not always completely
predictable, and resistance to novel molecular therapies is
commonly observed. Therefore, enhanced knowledge of can-
cer biology is further required to understand the diversity
of CRC patients, optimize individual therapies, and identify
novel targets for therapy [8–10]. To this end, it is expected
that proteomics will provide deeper insights into the biology
of CRC.
Studying the relationship between intra-tumor hetero-
geneity and functionally important genes may provide clues to
the mechanisms underlying the variable responses observed
following treatment in CRC. In addition, intra-tumor het-
erogeneity is of importance for drug-target and biomarker
discovery. The roles of particular mutations in intra-tumor
heterogeneity in CRC have been examined by multipoint
micro-sampling, and previous studies have identiﬁed genes
that are uniquely expressed in speciﬁc tissue areas [11–14].
In addition to the unique expression pattern of transcripts,
the protein expression proﬁles in particular lesions in tumor
tissues are interesting because of the general discordances
between the mRNA  and protein expression patterns [15–23].
In previous reports, we have investigated the protein
expression proﬁles of CRC tissue using two-dimensional dif-
ference gel electrophoresis (2D-DIGE) and our original large
format electrophoresis apparatus. When we  focused on pro-
teins with acidic pIs using immobilized pH gradient (IPG) gels
for the acidic range, we observed protein spots whose intensity
were different in the normal and tumor tissues from 59 CRC
patients. After protein identiﬁcation by mass spectrometry, in
particular, we  identiﬁed nuclear adenomatous poplyposis coli
binding protein EB1 as a novel prognostic biomarker in CRC
[24]. When focusing on proteins with alkaline pIs using IPG
gels for the alkaline rage, we  also observed proteins that were
aberrantly regulated in tumor tissues from 53 CRC patients,
and identiﬁed 6 proteins that had not been reported in CRC
[25]. For a more  detailed investigation of the proteome of CRC,
we recovered tumor cells from the ulcer ﬂoor, central area,
and invasive front, as well as normal colorectal epithelial cells
from surgical specimens by laser microdissection, and sub-
jected them to proteomic analyses using 2D-DIGE with IPG gels
for the acidic range [26]. We identiﬁed proteins with unique
functions that were speciﬁc to the tissue area of tumor cells
[26]. Such comprehensive approaches may contribute to our
understanding of the characteristics of CRC cells. Moreover,
the detailed clinical and pathological data of donors, inten-
sity of all protein spots, and detailed results of the protein
identiﬁcation by liquid chromatography–mass spectrometry
(LC–MS)/MS, were provided as useful information to enable
meta-proteome analysis of CRC [24–26].
Here, we investigated the proteomic content of the CRC
cells that localize to different regions in the tumor tissue.
We  recovered tumor cells by laser microdissection and cre-
ated protein expression proﬁles via 2D-DIGE, our original large
format electrophoresis apparatus, and IPG gels for the alka-
line rage. Protein expression patterns were compared between
the tumor cells (grouped according to tissue localization) and
normal epithelial cells. We identiﬁed proteins that were dif-
ferently regulated in particular tumor tissue regions, and had
functions that corresponded to the unique features of theor into non-peritonealized pericolic or perirectal tissues.
b Stage was determined according to the UICC TNM classiﬁcation.
speciﬁc site. Our study indicates the unique application of
laser microdissection and 2D-DIGE for tissue proteomics, and
provides a useful resource for CRC proteomics.
2.  Materials  and  methods
2.1.  Clinical  samples
This study included tumor and non-tumor tissue samples
from the randomly selected 19 CRC patients who  underwent
curative surgery at the National Cancer Center Hospital in
Japan. The clinicopathological observations for the patients
are summarized in Table 1, and the data from the individual
patients are listed in the Supplemental Table 1. None of the
patients received neoadjuvant chemotherapy before surgery.
Clinical staging was determined based on diagnostic imaging
criteria. Tumor and non-tumor tissues were obtained at the
time of surgery, snap-frozen in liquid nitrogen, and stored at
−80 ◦C until use. This study was approved by the ethics com-
mittee of the National Cancer Center, and written informed
consent was obtained from all the patients.
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/j.euprot.
2013.08.002.
2.2.  Laser  microdissection  and  protein  extraction
Laser microdissection was performed to recover speciﬁc cell
populations (Fig. 1A) [27,28]. In brief, 4-m and 8-m thick
frozen sections were prepared from tumor tissues and stained
with hematoxylin and eosin (HE) or hematoxylin alone,
respectively. The 4-m thick HE-stained tissues were used
e u  p a o p e n p r o t e o m i c s
Fig. 1 – Overview of two-dimensional difference gel
electrophoresis experiments. (A) Typical image of the
colorectal cancer tumor tissues stained with hematoxylin
and eosin (left panel). For the proteomic studies, the
neighboring sections were  stained with hematoxylin alone,
and the tumor cells were  recovered by laser microdissection
[28]. (B) Design of sample processing for two-dimensional
difference gel electrophoresis (2D-DIGE). The internal
standard sample and the individual sample were labeled
with Cy3 and Cy5, respectively. They were  mixed  together
and separated by two-dimensional polyacrylamide gel
electrophoresis. Note that 2 types of ﬂuorescent dye are
sufﬁcient for a study of multiple samples with an internal
standard sample [28]. (C) System reproducibility of 2D-DIGE
using the common internal standard sample was assessed
by examining an identical sample twice. The intensity of
96.2% of protein spots was scattered within 2-fold
differences, and the correlation coefﬁciency values for the
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ple groups. The protein spots with the intensity differencentensity of the protein spots were  >0.829.
or the microscopic observations (Fig. 1A, left panel), and
he 8-m thick hematoxylin-stained tissues were subjected
o laser microdissection (MMI  CellCut; Molecular Machines &
ndustries, Glattbrug, Switzerland; Fig. 1A, right panel). We
ecovered tumor cells from the different tissue areas, i.e., the
lcer ﬂoor, central area, and invasive front by laser microdis-
ection (illustrated in Fig. 1A). Laser microdissection was also
sed to recover noncancerous epithelial cells from normal 1 ( 2 0 1 3 ) 17–29 19
tissues that were a distance from the tumor tissues (image
data not shown). For each 2D-DIGE gel image,  1-mm2 area
of tumor tissue (approximately 3000 cells) was recovered. In
our previous study, we demonstrated that approximately 3000
cells were sufﬁcient for the 2D-DIGE experiments [27], and we
have reported the relevant protocols for this method [28]. The
proteins were extracted from the recovered tissues using a
urea lysis buffer (7 M urea, 2 M thiourea, 3% CHAPS, and 1%
Triton X-100) and stored at −80 ◦C until use.
2.3.  2D-DIGE  and  data  analysis
A protein expression proﬁle was created as described in a pre-
vious study [28]. In brief, an internal standard sample was
created by mixing an equal, small amount of all the individual
samples (illustrated in Fig. 1B). The internal standard and indi-
vidual samples were labeled with Cy3 and Cy5 ﬂuorescent dye
(CyDye DIGE Fluor saturation dye; GE Healthcare Biosciences,
Uppsala, Sweden), respectively. Equal amounts of these dif-
ferently labeled two types of protein samples were mixed
together, divided into three portions, and separated using two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE).
The ﬁrst dimension separation was achieved using immobi-
line pH gradient DryStrip gels (length 24 cm,  pI range 6–9; GE
Healthcare Biosciences). The protein samples were applied
to the immobiline pH gradient DryStrip gel by a cup-loading
method at the acidic end. Multiphor II was used for isoelec-
tric focusing gel electrophoresis (GE Healthcare Biosciences).
The second separation was performed using our original large
format electrophoresis apparatus with homemade gradient
gel and a separation distance of 33 cm using a large format
electrophoresis apparatus (Biocraft, Tokyo, Japan). After gel
electrophoresis, the gels were scanned using a laser scanner
(Typhoon Trio; GE Healthcare Biosciences) at the appropriate
wavelength for Cy3 or Cy5. For all the protein spots, the Cy5
intensity was normalized to the Cy3 intensity in the same gel
using the Progenesis SameSpots software version 3 (Nonlinear
Dynamics, Newcastle, UK), to compensate for gel-to-gel vari-
ations. All samples were examined in triplicate gels, and the
mean normalized intensity value was used for data-mining
purposes. The system reproducibility of 2D-DIGE with the
large format electrophoresis apparatus and common internal
standard sample was examined by running identical samples
twice.
2.4.  Statistical  analysis
The normalized and averaged spot intensity data were used
to identify the proteins with differential expression patterns.
Unsupervised classiﬁcation was employed to determine the
relationship between the overall proteomic data and the histo-
logical observations (Expressionist software; GeneData, Basel,
Switzerland). The Wilcoxon test was used to identify the spot
intensities that were signiﬁcantly different between the sam-with both p-value less than 0.01 and more  than 2-fold dif-
ferences were considered as those with different intensity
between two sample groups. The observed isoelectric points
o m i c20  e u  p a o p e n p r o t e 
were evaluated by measuring the electrophoretic mobility in
the isoelectric focusing.
2.5.  Mass  spectrometric  protein  identiﬁcation
Mass spectrometric protein identiﬁcation was performed
using the proteins extracted from the spot of interest. The
proteins were extracted as peptides by in-gel digestion accord-
ing to our previous report [28]. In brief, 100 g of the protein
sample was labeled with Cy5, and separated by 2D-PAGE as
mentioned above. The protein spots were recovered from
the gels by our original automated spot recover machine
[28], and then manually washed with acetonitrile and ammo-
nium bicarbonate solution. The washed protein spots were
treated with trypsin (Promega, Madison, WI)  at 37 ◦C overnight.
The trypsin digests were subjected to liquid chromatography
coupled with nanoelectrospray tandem mass spectrometry
(Finnigan LTQ linear ion trap mass spectrometer; Thermo
Electron Co., San Jose, CA). The Mascot software (version 2.2;
Matrix Science, London, UK) was used to search for the mass
of the peptide ion peaks against the SWISS-PROT database
(Homo sapiens, 471,472 sequences in the Sprot-57.5.fasta ﬁle).
Proteins with a Mascot score of 34 or more  were considered
to be positively identiﬁed. When single protein spots included
multiple proteins, the protein with the highest Mascot score
was assigned to the spot and demonstrated in Table 2, and
all identiﬁed proteins from the individual protein spots were
listed in Supplemental Table 3.
2.6.  Western  blotting
Protein samples extracted from frozen tissues with the urea
lysis buffer were used for western blotting. The clinicopatho-
logical observations for the patients are summarized in the
Supplemental Table 1. In brief, 5 g of the protein samples
were separated by SDS-PAGE using Criterion TGX Precast Gels
(Bio-Rad, Hercules, CA), and transferred to a nitrocellulose
membrane. The protein transfer was achieved using a con-
ventional western blotting buffer system. After blocking with
skimmed milk for 1 h, the membrane was incubated overnight
with antibodies against the following proteins; anterior gradi-
ent protein 2 (AGR2, 1:100; Abnova, Taipei, Taiwan), catalase
(1:1000; Sigma–Aldrich, St. Louis, MO), dermcidin (DCD, 1:100;
San Diego, CA), heat shock 70-kDa protein 8 (HSPA8, 1:800;
Proteintech Group, Chicago, IL), lamin A/C (1:100; Chemi-
con, Temecula, CA), pyruvate kinase muscle (1:250; Abgent,
San Diego, CA), TATA box binding protein-associated fac-
tor (1:4000; Gene Tex, Irvine, CA), and voltage-dependent
anion channel 1 (VDAC1, 1:100; Avia Systems Biology, San
Diego, CA). Subsequently, the membranes were treated with
the horse radish peroxidase-conjugated secondary antibody;
anti-rabbit IgG F (ab)2 fragment from donkey (1:2000; GE
Healthcare Biosciences) or anti-mouse IgG from sheep (1:2000;
GE Healthcare Biosciences). The membranes were processed
by enhanced chemoluminescence according to the manu-
facturer’s instruction (ECL Prime; GE Healthcare Biosciences).
After the membranes were scanned using LAS-3000 (FujiFilm,
Tokyo, Japan), they were stained with 0.2% Ponceau S and 1%
acetic acid (Sigma–Aldrich, St. Louis, MO), and the intensity
of the protein bands was measured using the ImageQuant s 1 ( 2 0 1 3 ) 17–29
software (GE Healthcare Biosciences). The intensity of the indi-
vidual protein bands was normalized using the intensity of a
lane from an identical membrane [29].
3.  Results
3.1.  Laser  microdissection  and  2D-DIGE  for  protein
expression  proﬁling
The tumor tissues were recovered from different areas, i.e., the
ulcer ﬂoor, central area, and invasive front by laser microdis-
section (Fig. 1A). Noncancerous epithelial cells were also
recovered by laser microdissection (data not shown). In total,
4 specimens were recovered from the surgically resected tis-
sue of each 19 CRC patient. The proteins were extracted from
the recovered cells and examined by 2D-DIGE. Fig. 1B shows
the design of the 2D-DIGE experiments, in which the common
internal standard sample was included in all data of individ-
ual samples. All samples were examined in triplicate gels, and
therefore, 228 2D-DIGE gels were used for the protein expres-
sion study (19 cases × 4 specimens × 3 gels). For all the protein
spots, the data obtained from the Cy5 image  were normal-
ized to those obtained from the Cy3 image. A scatter gram
was made from 2 independent experiments for an identical
sample; a laser microdissected tissue of the central area from
the No. 17 in the Supplemental Table 1 demonstrates the high
reproducibility of 2D-DIGE using a common internal standard
sample. Among the 2568 protein spots observed, the intensity
of 2471 spots were scattered within 2-fold differences (Fig. 1C).
Therefore, we considered greater than 2.0-fold differences in
spot intensity as being signiﬁcant in this study. A typical 2D
image is shown in Fig. 2, and the normalized and standardized
intensity of all the 2568 protein spots are summarized in the
Supplemental Table 2.
3.2.  Overview  of  the  proteomic  data  from  the  2D-DIGE
We observed the overall features of the proteome using the
2D-DIGE data to examine whether the samples would form 4
distinct cellular groups, i.e., normal epithelial cells, tumor cells
from the ulcer area, tumor cells from the center, or tumor cells
from the invasive front. The correlation matrix demonstrated
that the normal and tumor tissue samples had common pro-
tein expression proﬁles in the same sample group, while there
were no obvious sub-groups in the tumor samples (Fig. 3A). We
obtained similar results using principal component analysis of
the data (Fig. 3B). The samples were separated into normal and
tissue groups, and the tumor tissues were not clearly divided
according to their tissue localization. Indeed, there was no pro-
tein spot with an intensity that was signiﬁcantly (Wilcoxon
test, P < 0.01) and relevantly (>2.0-fold average intensity) dif-
ferent among the tumor tissues from the ulcer area, central
area, or the invasive front. In contrast, we  observed protein
spots with signiﬁcantly (Wilcoxon test, P < 0.01) and relevantly
(>2.0-fold average intensity) differences in intensity when we
compared the normal epithelial cells with the tumor cells
originating from the 3 different areas. Therefore, we  further
investigated those protein spots.
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Table 2 – Summary of the results of mass spectrometric protein identiﬁcation.
Spot no. Accession
no.
Protein description Ulcer ﬂoor vs
Normal
Central area vs
Normal
Invasive area
vs Normal
Expected
pI
Observed
pI
Classiﬁcationb
Ratio of
meansa
P-value Ratio of means1) P-value Ratio of
means1)
P-value
(A) A list of protein spots with statistically and signiﬁcantly increased intensity in ulcer ﬂoor, central area or invasive front compared with normal epithelial tissues
(Wilcoxon test, P < 0.01, >2-fold difference)
1677 P00338 L-lactate dehydrogenase A chain 1.010 1.27E−06 0.893 2.38E−06  0.784 1.63E−04 8.44 7.95 a
1822 P11142 Heat shock cognate 71 kDa protein 0.712 8.25E−03 0.936 4.21E−04  1.011 2.22E−03 5.37 7.72 i
1874 P35030 Trypsin-3 1.151 1.31E−05 1.080 2.19E−05 0.943 2.83E−04 7.46 8.75 e
1879 P05631 ATP synthase subunit gamma,
mitochondrial
1.080 5.79E−05 0.891 7.86E−05  1.004 1.85E−E−05 9.34 8.78 b
2388 P04406 Glyceraldehyde-3-phosphate
dehydrogenase
1.033  9.91E−03 1.566 2.83E−04 1.720 1.63E−04 8.57 8.28 d
2406 P81605 Dermcidin 1.042 2.76E−03 1.464 3.24E−04 1.652 1.42E−04 6.09 8.26 d
2560 P04406 Glyceraldehyde-3-phosphate
dehydrogenase
1.149  7.88E−04 1.651 1.56E−05 1.662 3.06E−05 8.57 7.73 d
2613 P07478 Trypsin-2 0.515 1.16E−01 1.039 5.43E−04 0.853 2.15E−02 4.78 7.68 f
2620 P04264 Keratin, type II cytoskeletal 1 1.018 6.20E−03 1.565 3.60E−05 1.615 9.13E−05 8.15 7.66 d
3475 P14618 Pyruvate kinase isozymes M1/M2 1.100 2.47E−04 1.330 3.55E−06 1.599 4.31E−06 7.96 6.34 d
3476 Q9NVA2 Septin-11 0.537 1.16E−01 0.841 4.23E−05  1.077 1.13E−03 6.36 6.34 h
3877 P13645 Keratin, type I cytoskeletal 10 0.614 4.62E−03 0.871 1.63E−04  1.076 1.31E−05 5.13 7.02 h
4011 P00338 L-lactate dehydrogenase A chain 1.089 9.04E−08 0.824 1.06E−04  0.867 2.59E−05 8.44 7.65 a
4012 P00338 L-lactate dehydrogenase A chain 1.155 1.53E−07 0.852 1.23E−04  0.860 3.24E−04 8.44 7.95 c
4014 P00338 L-lactate dehydrogenase A chain 1.074 6.79E−10 0.943 5.49E−09  1.024 3.79E−09 8.44 7.63 b
4015 P00338 L-lactate dehydrogenase A chain 1.182 1.70E−09 1.044 1.54E−08 1.023 3.06E−05 8.44 7.63 d
4016 P00338 L-lactate dehydrogenase A chain 0.981 8.21E−07 0.947 4.12E−07  1.103 7.87E−09 8.44 7.63 i
4019 P00338 L-lactate dehydrogenase A chain 1.040 2.19E−05 0.933 9.13E−05  0.972 4.31E−06 8.44 8.05 c
4031 P00338 L-lactate dehydrogenase A chain 1.197 1.94E−06 0.979 2.83E−04  0.891 1.59E−03 8.44 7.89 c
4046 P21796 Voltage-dependent anion-selective
channel protein 1
1.231 1.10E−08 1.049 3.79E−09 1.188 3.87E−08 8.62 7.61 d
4047 P21796 Voltage-dependent anion-selective
channel protein 1
1.016 2.38E−06 0.914 3.25E−07  1.085 9.04E−08 8.62 7.64 b
4070 P21796 Voltage-dependent anion-selective
channel protein 1
0.939 5.79E−05 1.106 3.55E−06 1.290 2.38E−06 8.62 6.74 g
(B) A list of protein spots with statistically and signiﬁcantly decreased intensity in ulcer ﬂoor, central area or invasive front compared with normal epithelial tissues
(Wilcoxon test, P < 0.01, >2-fold difference)
523 A8K714 Calcium-activated chloride
channel regulator 1
−1.373  6.97E−04 −1.276 1.78E−03 −1.108 9.05E−03 5.90 7.76 o
569 A8K714 Calcium-activated chloride
channel regulator 1
−1.311  9.05E−03 −0.924 1.68E−02  −0.876 2.33E−02 5.90 7.53 j
587 P07477 Trypsin-1 −1.355 9.91E−03 −0.986 1.68E−02  −0.884 1.41E−02 6.08 7.53 j
589 A8K714 Calcium-activated chloride
channel regulator 1
−1.184  2.59E−05 −1.000 4.79E−04  −0.941 4.21E−04 5.90 7.08 j
590 A8K714 Calcium-activated chloride
channel regulator 1
−1.989  1.27E−06 −1.644 4.95E−05 −1.680 1.56E−05 5.90 7.33 o
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Table 2 – (Continued)
Spot no. Accession
no.
Protein description Ulcer ﬂoor vs
Normal
Central area vs
Normal
Invasive area
vs Normal
Expected
pI
Observed
pI
Classiﬁcationb
Ratio of
meansa
P-value Ratio of means1) P-value Ratio of
means1)
P-value
596 A8K714 Calcium-activated chloride
channel regulator 1
−1.053  1.27E−03 −0.994 1.99E−03 −1.059 1.99E−03 5.90 7.55 k
1058 P04264 Keratin, type II cytoskeletal 1 −0.991 4.23E−05  −0.813 7.86E−05 −1.003 9.44E−06 8.15 7.61 t
1151 P54868 Hydroxymethylglutaryl-CoA
synthase, mitochondrial
−0.980 6.83E−03  −1.211 1.85E−05 −1.204 2.59E−05 8.40 6.50 s
1719 Q32P51 Heterogeneous nuclear
ribonucleoprotein A1-like protein 2
−0.711 4.21E−04  −0.886 1.53E−07 −1.026 1.57E−06 9.08 8.58 t
1720 P56470 Galectin-4 −0.687 2.16E−04  −0.946 9.04E−08 −1.032 1.18E−07 9.21 8.66 t
1797 P40926 Malate dehydrogenase,
mitochondrial
−1.224  9.04E−08 −0.952 1.31E−05 −1.041 2.19E−05 8.92 6.46 l
1815 P04264 Keratin, type II cytoskeletal 1 −1.165 1.57E−06 −0.727 6.16E−04 −0.957 3.60E−05 8.15 6.39 j
1825 P35030 Trypsin-3 −1.017 6.32E−06 −0.878 1.31E−05 −0.811 1.23E−04 7.46 6.42 j
1936 P52272 Heterogeneous nuclear
ribonucleoprotein M
−1.009  5.79E−05 −0.550 6.83E−03 −0.708 2.76E−03 8.84 6.26 j
1952 P17931 Galectin-3 −0.742 1.27E−03  −0.860 1.88E−04 −1.056 3.06E−05 8.58 7.82 t
1966 P15559 NAD(P)H dehydrogenase [quinone]
1
−1.044 8.21E−07 −0.796 3.55E−06 −0.852 2.91E−06 8.91 6.10 j
1987 P01834 Ig kappa chain C region −1.136 5.49E−09 −0.806 2.38E−06 −0.938 6.86E−08 5.58 6.10 j
2037 P00918 Carbonic anhydrase 2 −1.234 7.87E−09 −1.095 1.54E−08 −1.162 2.87E−08 6.87 6.73 o
2047 P81605 Dermcidin −1.304 1.54E−08 −1.065 4.12E−07 −1.092 1.94E−06 6.09 6.77 o
2060 P01834 Ig kappa chain V-III region SIE −1.009 1.85E−05 −0.404 4.62E−02 −0.494 1.54E−02 5.58 7.21 j
2064 P01834 Ig kappa chain C region −1.949 2.55E−09 −1.776 1.13E−10 −1.857 7.87E−09 5.58 6.88 o
2076 P02768 Serum albumin −1.130 3.55E−06 −0.589 4.95E−05 −0.852 2.83E−04 5.92 6.78 j
2099 P01834 Ig kappa chain V-III region SIE −1.162 6.32E−06 −0.943 3.60E−05 −1.108 2.91E−06 5.58 7.58 l
2692 O95994 Anterior gradient protein 2
homolog
−1.044 5.43E−04 −1.041 7.88E−04 −1.038 2.76E−03 9.03 8.84 n
2758 Q16378 Proline-rich protein 4 −1.396 7.61E−06 −0.974 1.59E−03 −1.276 4.21E−04 6.50 7.76 l
3075 Q92804 TATA-binding protein-associated
factor 2 N
−1.868 2.19E−05 −1.591  1.13E−03 −1.582 4.79E−04 8.04 7.57 o
3078 A8K714 Calcium-activated chloride
channel regulator 1
−1.831  7.88E−04 −1.667 3.77E−03 −1.690 1.27E−03 5.90 7.56 o
3338 P02545 Lamin-A/C −1.490 2.11E−08  −1.241 9.04E−08 −1.065 2.38E−06 6.57 6.15 o
3342 P04040 Catalase −1.262 3.79E−09  −1.102 1.18E−07 −0.955 1.56E−05 6.90 6.60 p
3461 P25705 ATP synthase subunit alpha,
mitochondrial 1
−0.824 6.32E−06  −1.032 1.02E−06 −1.074 2.87E−08 9.16 7.11 r
3517 P54868 Hydroxymethylglutaryl-CoA
synthase, mitochondrial
−1.009 1.00E−03  −0.941 5.43E−04 −0.902 6.16E−04 8.40 6.53 j
3518 P14618 Pyruvate kinase isozymes M1/M2 −0.788 4.62E−03  −1.062 1.23E−04 −0.974 1.59E−03 7.96 6.49 q
3519 P02768 Serum albumin −1.322 1.78E−03  −1.582 9.13E−05 −1.415 1.88E−04 5.92 6.50 o
3541 P54868 Hydroxymethylglutaryl-CoA
synthase, mitochondrial
−1.578 8.89E−04  −1.639 7.86E−05 −1.569 7.86E−05 8.40 6.53 o
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Table 2 – (Continued)
3550 P12532 Creatine kinase, ubiquitous
mitochondrial
−0.844 6.83E−03  −0.997 4.79E−04 −1.074 8.89E−04 8.60 7.42 t
3594 P12532 Creatine kinase, ubiquitous
mitochondrial
−0.860 4.79E−04  −1.012 1.85E−05 −1.003 2.59E−05 8.60 7.12 r
3882 P17174 Aspartate aminotransferase,
cytoplasmic
-1.130 2.55E−09 −0.963  3.25E−07 −0.725 4.23E−05 6.53 7.02 j
3887 P04264 Keratin, type II cytoskeletal 1 −1.272 3.79E−09 −0.943 3.55E−06  −0.913 1.27E−06 8.15 6.14 m
3902 P45954 Short-chain speciﬁc acyl-CoA
dehydrogenase, mitochondrial
-1.012 4.31E−06 −0.971 5.21E−07 −0.831  7.61E−06 6.53 6.08 j
4064 P09651 Heterogeneous nuclear
ribonucleoprotein A1
−0.708 1.63E−04 −1.038 2.54E−07 −1.117 1.31E−05  9.17 8.86 r
4150 P00915 Carbonic anhydrase 1 −1.653 1.63E−04  −1.699 1.18E−07 −1.894 1.54E−08 6.59 6.57 o
4154 P00915 Carbonic anhydrase 1 −1.065 3.79E−09  −0.919 1.98E−07 −0.892 5.18E−08 6.59 6.14 j
4169 P01834 Ig kappa chain C region −1.178 6.86E−08  −0.821 8.21E−07 −0.913 2.11E−08 5.58 6.09 j
4176 P00918 Carbonic anhydrase 2 −2.204 9.04E−08  −2.224 1.70E−09 −2.344 5.66E−11 6.87 6.84 o
4177 P00918 Carbonic anhydrase 2 −2.065 4.12E−07  −2.224 6.79E−10 −2.133 6.79E−10 6.87 6.84 o
4182 P00918 Carbonic anhydrase 2 −2.171 1.18E−07  −2.373 1.13E−10 −2.258 5.66E−11 6.87 6.86 o
4183 P00918 Carbonic anhydrase 2 −1.438 3.79E−09  −1.238 2.11E−08 −1.133 2.54E−07 6.87 6.60 o
4186 P02768 Serum albumin −1.347 1.10E−08  −1.111 3.55E−06 −1.188 2.54E−07 5.92 6.73 o
4188 P21796 Voltage-dependent anion-selective
channel protein 1
−1.009 3.06E−05  −0.837 1.06E−04 −0.943 9.13E−05 8.62 6.74 j
4376 O95994 Anterior gradient protein 2
homolog
−1.020 2.76E−03  −1.086 2.76E−03 −1.074 8.25E−03 9.03 8.79 n
4377 O95994 Anterior gradient protein 2
homolog
−0.969 2.76E−03  −1.012 5.10E−03 −1.099 2.76E−03 9.03 8.82 r
4378 O95994 Anterior gradient protein 2
homolog
−0.842 2.76E−03  −0.952 8.89E−04 −1.038 6.97E−04 9.03 8.89 t
4418 P02768 Serum albumin −1.044 3.40E−03  −0.997 1.30E−02 −1.234 2.22E−03 5.92 7.59 l
Bold:  Values of ratio of means and p value for signiﬁcant differences between normal and tumor tissues. Italic: Value of expected isoelectric point outside 6–9.
a The base-2 logarithm of the mean ratio.
b The classiﬁcations a–t corresponded to those in Fig. 5.
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Fig. 2 – A representative image of the colorectal cancer
tissue proteome obtained by 2D-DIGE. Cy3 labeled protein
samples were  separated by isoelectric focusing
electrophoresis and SDS-PAGE. The numbers correspond to
those indicated in the Supplemental Table 2, in which the
normalized and averaged intensity of the 2568 protein
spots is summarized.
Fig. 3 – Overall features of the colorectal cancer proteome analyz
correlation coefﬁciency between the 2D-DIGE data demonstrates
histological classiﬁcation, normal epithelial cells, and tumor cell
based on the intensity of the 2568 protein spots. The samples w
normal epithelial cells and tumor cells. The tumor cells were  not s 1 ( 2 0 1 3 ) 17–29
3.3.  Comparison  between  the  normal  epithelial  cells
and the  tumor  cells  with  different  tissue  localizations
We compared the intensity of the 2D-DIGE data from the nor-
mal  epithelial cells and the 3 tumor tissue groups. Among
the 2568 protein spots, we observed 57, 35, and 49 protein
spots that had signiﬁcantly (Wilcoxon test, P < 0.01) and rel-
evantly (>2.0-fold average intensity) differences in intensity
when the normal epithelial cells were compared to the tumor
cells from the ulcer ﬂoor, central area, and invasive front,
respectively (Fig. 4A–C). When all the tumor samples were
grouped together, irrespective of the tissue areas from which
they originated, and the spot intensity was averaged, 40 pro-
tein spots showed signiﬁcantly (Wilcoxon test, P < 0.01) and
relevantly (>2.0-fold average intensity) differences between
the normal epithelial cells and tumor cells (Fig. 4D).  The results
of the mass spectrometric protein identiﬁcations are shown on
the right side of the heat map  (Fig. 4A–D). The localization of
these protein spots on the 2D image  is demonstrated in Fig. 2.
In addition, the intensity of each protein spot is summarized in
the Supplemental Table 2 and the supporting peptide data for
protein identiﬁcation is shown in the Supplemental Table 3.
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/j.euprot.
2013.08.002.
3.4.  Comparison  between  the  normal  epithelial  cells
and the  ungrouped  tumor  cells
The number of protein spots with different intensity between
the different tissue areas is summarized in Venn diagrams
(Fig. 5). When all the tumor samples originating from different
tissue areas were grouped together as the whole tumor tissue
and the spot intensity was averaged, 17 and 23 protein spots
showed signiﬁcantly (Wilcoxon test, P < 0.01) and relevantly
(>2.0-fold average intensity) higher and lower intensities in
the tumor cells compared with the normal epithelial cells
(Fig. 5). In contrast, 5 and 23 protein spots were found to have
signiﬁcantly (Wilcoxon test, P < 0.01) and relevantly (>2.0-fold
average intensity) higher-intensities and lower-intensities,
ed by 2D-DIGE. (A) The correlation matrix based on the
 the similarity between the samples of the same
s. (B) Principal component analysis of protein samples
ere divided into 2 groups by principal component analysis:
 divided according to their tissue localization.
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Fig. 4 – Proteins with differential expression levels in normal colorectal epithelial tissues and tumor tissues. Protein spots
with different intensities in the normal epithelial cells and tumor cells of the ulcer ﬂoor (A), central area (B), and invasive
front (C) are indicated. The intensity is displayed in the form of a heat map.  The protein spots with different intensities in
the normal epithelial cells and ungrouped tumor cells according to tissue localization are also exhibited as a heat map  (D).
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upporting data for protein identiﬁcation are shown in the S
espectively, in tumor cells with different tissue localizations,
ompared with the normal epithelial cells (Fig. 5A and B).
hen we  averaged the data of tumor cells without consider-
ng the tumor cell localization, we observed 7 and 16 protein
pots that had intensities that were higher and lower in all
umor samples, compared with the normal epithelial cells,
espectively (Fig. 5).In this study, 75 protein spots were subjected to mass
pectrometric protein identiﬁcation. These 75 protein spots
orresponded to 38 unique proteins (Table 2). According to the
mino acid sequences, the expected isoelectric points of theental Table 2. A list of the identiﬁed proteins and the
lemental Table 3.
proteins for the 50 protein spots (50/75, 66.7%) were between
6 and 9, and the isoelectric points of the proteins from the
other spots were out of this range (Table 2). Even for the pro-
teins with isoelectric points between 6 and 9, the expected and
observed isoelectric points differed (Table 2).
3.5.  Validation  of  the  results  of  the  comparative  study
and protein  identiﬁcation
The differences in expression levels of the identiﬁed proteins
in the normal and tumor tissues were conﬁrmed by western
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Fig. 5 – Summary of the proteins identiﬁed using
comparative studies. Venn diagrams of the protein spots
with different intensities between the sample groups. The
number of protein spots with increased or decreased
intensity in the tumor cells compared with the normal
epithelial cells is shown in the Venn diagrams (A and B,
respectively). The number of protein spots that have varied
intensities in the normal epithelial cells compared to the
ungrouped tumor cells is shown. The letters in brackets
Fig. 6 – Western blot analyses for the 8 identiﬁed proteins.
The expression levels of the 8 proteins were  examined by
western blot analysis. The sample numbers correspondedcorrespond to the category indicated in Table 2.
blot analysis using 8 antibodies (Fig. 6). Among the 8 proteins
examined, HSPA8 showed higher expression level in both 2D-
DIGE and western blotting experiments. The other proteins
did not show such concordance.
4.  Discussion
We  identiﬁed the proteins that had been previously reported
to be aberrantly expressed and clinically signiﬁcant in CRC.
These proteins included heterogenous nuclear ribonucleopro-
tein A1 [30], galectin-3 [31], galectin-4 [32], VDAC1 [33], and
AGR2 [33]. In the previous report, AGR2 was up-regulated in
amount in tumor tissues compared with normal epithelial tis-
sues in CRC cases [33]. However, we found that the expression
of AGR2 was down-regulated in tumor tissues (Table 2). AGR2
was originally discovered as a secretory factor in the ante-
rior region of the dorsal ectoderm in Xenopus laevis embryosto those in the Supplemental Table 1.
[34]. AGR2 inhibited p53 [35,36], and played important roles
in tumor growth, cellular transformation, cell migration, and
metastasis. Overexpression of AGR2 has been reported in
various cancers [36–38], and lower expression of AGR2 is asso-
ciated with poor prognosis in lung adenocarcinoma [39]. In
our study, 3 forms of AGR2 were observed in different tissue
locations and all had lower expression levels in the tumor
tissues (Fig. 5 and Table 2). This is the ﬁrst report describ-
ing the down-regulation of AGR2 in CRC. However, as western
blotting demonstrated that the expression level of AGR2 var-
ied among the cases, and was discordant with 2D-DIGE data,
the further investigations on the individual isoforms of AGR2
may be required to conﬁrm the biological signiﬁcances of our
ﬁndings. We  also found a unique regulation of protein forms
by measuring intensity of individual protein spots. VDAC1
is a mitochondrial membrane protein that is responsible for
the regulation of apoptosis [40,41], and considered to be a
promising drug target [42]. The aberrant expression and clini-
cal signiﬁcance of VDAC1 have been reported in many  cancers
[43–46] including CRC [33]. In this report, 4 forms of VDAC1
were identiﬁed as proteins that are differently expressed in
tumor tissues compared to normal epithelial cells with statis-
tical signiﬁcances; one form (spot 4046) were up-regulated in
all 3 types of tumor tissues, and 1 was up-regulated in inva-
sive area and ulcer ﬂoor (spot 4047) or central area (spot 4070).
One form (spot 4188) was decreased in amount in ulcer ﬂoor
area (Fig. 5 and Table 2). These observations may suggest the
unique aspects of proteomic study by 2D-DIGE. DCD was a
secreted protein that is subsequently processed into proteins
with smaller molecular weight and distinct biological proper-
ties. Overexpression of DCD is associated with poor prognosis
in breast cancer [47]. The proteolytically processed C-terminal
peptide of DCD has antimicrobial activity against a variety of
pathogenic microorganisms [48]. It is noteworthy that a glyco-
sylated form of the N-terminal peptide of DCD is associated
with cachexia [49]. Although the downstream proteins of DCD
have been extensively investigated [50], the role of DCD  has
not been reported in CRC. In our study, 2 protein spots for
DCD were observed as proteins with higher and lower expres-
sion levels in all 3 portions of the tumor tissues compared
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ith the normal epithelial cells (Fig. 5 and Table 2). These 2
CD forms may play distinct roles in CRC tissues, and further
haracterization will be of interest.
2D-DIGE using laser microdissection became a practical
ool for cancer research following the introduction of the
ighly sensitive ﬂuorescent dye CyDy DIGE Fluor saturation
ye [51,27]. The sensitivity of conventional silver staining is
elatively low, and it took tremendous time to recover enough
ells for proteomic analysis [52]. 2D-DIGE with laser microdis-
ection is an established method [28] and is recognized as
 useful tool in cancer research [53]. 2D-DIGE using highly
ensitive ﬂuorescent dye can be applied to a large number
f laser microdissected clinical samples. Moreover, the com-
ination of 2D-DIGE using highly sensitive ﬂuorescent dye
ith a laser machine enables detailed proteomics of cellular
rganelles such as psuedopodia of breast cancer cells, thereby
esulting the identiﬁcation of metastasis-associated proteins
54].
Although proteomic methods using laser microdissec-
ion are technically established, they have fundamental
imitations, and require further investigation. First, laser
icrodissection recovers only limited tissues from tumors,
nd therefore the recovered sample may not accurately rep-
esent the whole tissue. In tissue microarrays (TMA), where
mall tissues are prepared from donor tissue parafﬁn blocks
nd arrayed on glass slides, multiple samples from single tis-
ues are examined for population studies [55,56]. However,
t is suggested that full sections rather than TMA  should
e examined for an accurate assessment of human epider-
al  growth factor receptor 2 [57]. In our study, one tissue
ample with typical histological appearances was recov-
red from 3 morphologically distinct areas of 19 tumor
issues. Multiple sampling from the same tissue areas, and
ampling from the areas deﬁned by genomics and imag-
ng may be required to improve the present experimental
esign. Secondly, we examined only tumor cells, avoiding
he ﬁbroblasts, vascular endothelial cells, and inﬂammatory
ells. Previous proteomic studies demonstrated the unique
haracteristics of cancer-associated ﬁbroblasts (CAFs) [58],
nd factors responsible for the interaction between can-
er cells and CAFs have been reported [59]. Aberrant tumor
ngiogenesis induced by vascular endothelial growth fac-
or and the Notch signaling pathway has been considered
s a cancer drug target [60]. Therefore, studies focused on
hese cell components using a laser microdissection pro-
eomic approach is of great interest. Thirdly, the number and
haracteristics of the proteins observed by 2D-DIGE are lim-
ted, and therefore, complement technologies such as those
ased on mass spectrometry and antibodies are required
or a comprehensive study. Each proteomics modality has
dvantages and limitations, and it is unlikely that an abso-
ute method will appear in the near future. Therefore, the
omplementary use of presently available technologies is
equired to further our understanding of intra-tumor hetero-
eneity.
Our past and present studies suggest that it may be nec-ssary to investigate the advantages of laser microdissection
n a proteomic study. When we examined proteins with alka-
ine pIs using homogenized CRC tissue samples and 2D-DIGE, 1 ( 2 0 1 3 ) 17–29 27
we observed 1687 protein spots and found 45 and 55 protein
spots with higher intensities in the tumor and normal tissues,
respectively [25]. In this study, which used laser microdis-
sected tissues, the number of observed protein spots was 2568,
which is 881 more  spots than the previous study using homog-
enized tissue samples, 22 and 53 protein spots were identiﬁed
as having higher intensities in the tumor and normal tissues.
In addition, we also observed differences in the proteomic
studies using the IPG gels for the acidic pI range with or with-
out laser microdissection [24,26]. The factors attributable to
the differences between the experiments using homogenized
tissue samples and those using laser microdissected samples
include the different population of cells subjected to the anal-
ysis, the artiﬁcial loss of protein during the procedure of tissue
staining and laser microdissection, and the possible differ-
ences in the labeling efﬁciency of the ﬂuorescent dyes. We  will
assess these issues in the future using identical tissue samples
and homogenization or laser microdissection.
The protein identiﬁcation and protein expression levels
were examined by western blot analysis using homogenized
tissue samples. Among the 8 proteins we examined, HSPA8
showed higher expression in tumor tissues in both 2D-
DIGE and western blotting experiments. The discordances
between SDS-PAGE/western blot analysis and 2D-PAGE may
be attributable to the location of protein isoforms, pIs of the
proteins, and the speciﬁcity and dynamic range of the antibod-
ies. These observations suggest that for the further validation
study on the expression level of each protein isoforms, we  may
need antibody speciﬁc to each protein spots. Alternatively,
the quantitative evaluation of proteins by multiple reaction
monitoring (MRM) will be a possible solution [61]. It will be a
challenge to examine a small amount of proteins in the protein
spots by MRM.
2D-PAGE and 2D-DIGE are extensively used in protein
expression studies in various ﬁelds including cancer research.
Most studies have focused on proteins with acidic pIs using IPG
gels with pI ranges between 4 and 7, probably due to difﬁculties
in isoelectric focusing of proteins with basic pIs. We  revealed
that the expected isoelectric points of 66.7% of proteins iden-
tiﬁed in our study were between 6 and 9, and therefore, are not
observable by isoelectric focusing for acidic proteins (Table 2).
The combination of IPG gels with different isoelectric focus-
ing range will be require for the global expression study by
2D-DIGE. Even for the popular research theme, novel ﬁndings
are expected by using the IPG gels for the isoelectric focusing
ranges that were not examined.
Proteomic data from our studies using CRC tissues provide
a useful resource together with our previous reports [24–26].
We published the intensity of all the protein spots that we
observed with acidic and alkaline pIs using 2D-DIGE, our orig-
inal large format electrophoresis, and IPG gels of 24 cm length.
Moreover, we published the detailed clinical and pathological
data of the CRC patients and the protein identiﬁcation data by
LC–MS/MS. In a series of the studies, the proteins were pre-
pared from homogenized or laser microdissected tissues, and
the effects of protein extraction on the proteome data can be
examined. The integration of these proteomic data and the
comparison of the CRC data from other reports will be intrigu-
ing.
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